Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
What does participation in a MiraKind study entail?
MiraKind will review your application once you take the eligibility survey to apply for a study. Once you have submitted your sample you can elect to receive your KRAS-variant results, which we will share with a physician of your choice, for a fee of $295. However, participation in a study is free if you do not want to receive your results. At the completion of the study, we will conduct a webinar to communicate the research findings and answer questions from participants.
What are the benefits of participating in a Mirakind study?
The greatest benefit to participation is knowing that you are helping to find answers that can ultimately save lives and prevent cancer. If you also choose to learn your KRAS-variant status as part of the process of participating in a study, this knowledge may help you make healthcare decisions into the future. However, whether or not you choose to learn your KRAS-variant status, we welcome you to be part of the MiraKind community where you will have access to support, education, and cutting edge research on the KRAS-variant and other inherited genetic differences associated with cancer risk.
Qualification depends on the parameters of the study. Complete our eligibility survey and we will let you know the studies for which you are eligible to participate.Can I get my individual KRAS-variant results as part of my participation?
Individual results are available for study participants, at a discounted rate of $295 to cover the base cost of testing through our sister CLIA lab, MiraDx.
How much does it cost to participate in a study?
There is no fee to participate in a study.
Are MiraKind studies under an IRB Protocol?
Yes, our studies are all conducted under an IRB approved Protocol.
Can I participate in more than one MiraKind study?
Yes, you are welcome to participate in as many studies as you wish, as long as you meet the study criteria.
How are study topics determined?
All of our studies focus on developing and understanding patient-centered applications of important genetic markers. Our goal is to enhance health, well-being and prevent cancer for as many individuals as possible. We choose topics based on the most pressing research questions at the time of the study and always welcome suggestions for study topics from members of the MiraKind community.
Can men participate in your studies?
What does MiraKind do with my information if I don’t qualify for a study?
If you do not meet study criteria, MiraKind holds your information to determine your eligibility for upcoming studies.
What happens to my data if I do participate in a study?
If you participate in a study, your data will be used in that study and be kept strictly confidential. We will never share your data with others.
What do KRAS-variant results mean for me?
Please read Understanding Results to better understand what being positive, or negative for the KRAS-variant may mean for you.
How accurate are the results?
Results of your genetic KRAS-variant results are >99.9% accurate. This does not indicate that you will or will not develop cancer but rather that you carry a gene mutation which is associated with an increased risk of certain cancers.
What do I do if I find out I am positive for the KRAS-variant?
If you receive a positive test result, you should consult with your physician and a MiraKind physician will be available to provide support along the way. As well, the MiraKind community is made up of individuals who have either tested positive for the KRAS-variant and/or who have family members who have tested positive or have a history of cancer. We have created this community with the aim of supporting individuals in their healthcare decisions, to connect them with each other, and to provide MiraKind members with access to the latest research on the KRAS-variant.